Lv5
1280 积分 2021-12-01 加入
Tenecteplase for Stroke at 4.5 to 24 Hours
17天前
已完结
Alirocumab: First Global Approval
24天前
已完结
Accelerated approvals: Early-phase success or premature authorization?
1个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2个月前
已完结
The present and future of bispecific antibodies for cancer therapy
2个月前
已完结
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
2个月前
已完结
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2个月前
已完结
Cancer immunoediting and resistance to T cell-based immunotherapy
2个月前
已完结
Hypoxia as a driver of resistance to immunotherapy
2个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
